+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Quality of Life Among Patients with Multiple Sclerosis Treated with Prolonged-Release Fampridine 10 Mg Tablets for Walking Impairment



Quality of Life Among Patients with Multiple Sclerosis Treated with Prolonged-Release Fampridine 10 Mg Tablets for Walking Impairment



Value in Health 17(7): A401-A402




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058669971

Download citation: RISBibTeXText

PMID: 27200955

DOI: 10.1016/j.jval.2014.08.918


Related references

Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis. Expert Review of Neurotherapeutics 13(12): 1309-1317, 2014

Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability. Drugs 77(14): 1593-1602, 2017

A guide to treating gait impairment with prolonged-release fampridine (Fampyra ® ) in patients with multiple sclerosis. Neurologia 33(5): 327-337, 2016

Treatment Costs and Patterns In Patients With Multiple Sclerosis Treated With Prolonged-Release Fampridine In Germany. Value in Health 18(7): A753, 2015

Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. Multiple Sclerosis 22(11): 1463-1475, 2016

PND5 Budget Impact of Oral Prolonged-Release Fampridine for Management of Walking Disability Associated With Multiple Sclerosis in Taiwan. Value in Health 15(7): A675-A676, 2012

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine). Bmc Neurology 15: 171, 2016

Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets. Degenerative Neurological and Neuromuscular Disease 2: 53-64, 2019

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS). Cns Neuroscience and Therapeutics 19(5): 302-306, 2013

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. Cns Drugs 2018, 2018

Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. Clinical Therapeutics 31(10): 2206-2214, 2010

Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Clinical Therapeutics 31(10): 2215-2223, 2010

Long-term safety and efficacy of prolonged-release fampridine in Japanese patients with multiple sclerosis (MS): Results from the motion-Japan Part b study. Journal of the Neurological Sciences 381: 779-780, 2017

Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. Expert Review of Clinical Pharmacology 5(6): 649-665, 2013

Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study. Journal of the Neurological Sciences 395: 106-112, 2018